Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP earnings Wednesday of $0.69 per diluted share, up from $0.60 a year earlier.
Analysts polled by Capital IQ expected $0.66.
Net revenue for the quarter ended Sept. 30 was $4.33 billion, up from $3.85 billion a year earlier.
Analysts polled by Capital IQ expected $4.13 billion.
The company said it now expects full-year 2024 non-GAAP diluted EPS of $2.40 to $2.50, compared with $2.30 to $2.50 previously. Analysts surveyed by Capital IQ expect $2.45.
Revenue for the year is now expected to be from $16.1 billion to $16.5 billion, from a prior guidance of $16 billion to $16.4 billion. Analysts surveyed by Capital IQ expect $16.26 billion.
Shares of the company were up 3.9% in recent Wednesday premarket activity.
Price: 19.50, Change: +0.73, Percent Change: +3.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.